Svolta della FDA, via libera negli Stati Uniti al nuovo farmaco contro il tumore al pancreas: i test clinici mostrano una sopravvivenza raddoppiata

RAS inhibitor daraxonrasib doubled survival outcomes in second-line trial

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.